Shots:
- The P-III (ASCENT-03) trial (n= 558) assessed Trodelvy (sacituzumab govitecan-hziy; 10mg/kg, IV, Day 1 & 8 of 21-day cycle) vs CT in 1L pts with locally advanced, inoperable, or metastatic TNBC without PD-L1 expression or PD-L1+ pts who were previously treated with a PD-L1 inhibitor
- Trial met its 1EP of improved PFS by 38% (mPFS: 9.7 vs 6.9mos.) in pts ineligible for PD-1/PD-L1 inhibitors, with consistent PFS benefit seen across all subgroups, incl. pts with poorer prognosis & regardless of CT chosen
- Trial also showed an ORR of 48% vs 46%, with mDoR of 12.2 vs 7.2mos.; OS (2EP) data remains immature & will be assessed later. Results were published in The NEJM
Ref: Gilead| Image: Gilead| Press Release
Related News:- Gilead Reports the EC’s Approval of Yeytuo (Lenacapavir) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV in Individuals at Risk
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
